#Cholangiocarcinoma Market Forecast
Explore tagged Tumblr posts
Visit Tumblr Blog
Explore Tumblr blogs with no restrictions, modern design and the best experience.
Last Seen Tumblr Blogs
Fun Fact
In 2020, Tumblr had 29.4 million users in the US.
Text
https://social.studentb.eu/read-blog/178810_cholangiocarcinoma-market-share-overview-competitive-analysis-and-forecast-2031.html
The Cholangiocarcinoma Market in 2023 is US$ 236.82 million, and is expected to reach US$ 630.46 million by 2031 at a CAGR of 13.00%.
0 notes
Text
Radiofrequency Ablation (RFA) Devices Market to Witness 9.37% CAGR Growth Between 2024 and 2030
According to a recent comprehensive by MarkNtel Advisors Radiofrequency Ablation (RFA) Devices Market research report, the Radiofrequency Ablation (RFA) Devices market is set for significant growth, driven by factors such as market size, share, and evolving trends.
This detailed report offers crucial insights into the market, covering key aspects such as market segmentation and definitions. It outlines the main drivers of growth and provides a clear forecast of the industry’s future direction. Additionally, the study provides a thorough overview of the competitive landscape, detailing recent developments and regional distribution across major areas. An expert competitor analysis delivers an in-depth understanding of market dynamics, offering strategic recommendations for businesses and investors.
✅In case you missed it, we are currently revising our reports. Click on the below to get the latest research data with forecast for years 2025 to 2030, including market size, industry trends, and competitive analysis. It wouldn’t take long for the team to deliver the most recent version of the report.
With its robust analysis and forward-looking projections, this report is an essential resource for stakeholders aiming to leverage emerging opportunities and address potential challenges in the Radiofrequency Ablation (RFA) Devices market.
Get a Sample PDF of Report - https://www.marknteladvisors.com/query/request-sample/radiofrequency-ablation-devices-market.html
Radiofrequency Ablation (RFA) Devices Market (2024-2030): Analysis and Growth
The Global Radiofrequency Ablation (RFA) Devices Market is estimated to grow at a CAGR of around 9.37% during the forecast period, i.e., 2024-30
What are the key drivers fueling growth in the Radiofrequency Ablation (RFA) Devices market from 2024-2030?
Increasing Incidences of Gastrointestinal Diseases to Drive Market Growth – Globally, some of the important thing illnesses that RFA devices have these days include cholangiocarcinoma, esophageal squamous mobile dysplasia, and so forth. Therefore, due to their expanded prevalence, specifically throughout growing countries like Brazil, India, Mexico, etc., the demand for RFA gadgets has stepped forward. Also, the incidence of gastrointestinal infections has appreciably long gone up, and this has been fueling demand for much less invasive approaches along with RFA gadgets for functions of treatment.
Radiofrequency Ablation (RFA) Devices Market : Segmentation Analysis
-By Product Type
-Radiofrequency Generators- Market Size & Forecast 2019-2030, USD Million
-Consumables- Market Size & Forecast 2019-2030, USD Million
-Radiofrequency Electrodes- Market Size & Forecast 2019-2030, USD Million
-Radiofrequency Probes- Market Size & Forecast 2019-2030, USD Million
-Radiofrequency Catheters- Market Size & Forecast 2019-2030, USD Million
-Radiofrequency Cannulas- Market Size & Forecast 2019-2030, USD Million
-Others (RF Needles, Grounding Pads, etc.)- Market Size & Forecast 2019-2030, USD Million
-By Procedure Type
-Bipolar Radiofrequency Ablation- Market Size & Forecast 2019-2030, USD Million
-Unipolar Radiofrequency Ablation- Market Size & Forecast 2019-2030, USD Million
-Others (Pulsed RFA, Laser RFA, etc.) - Market Size & Forecast 2019-2030, USD Million
-By Application
-Cardiology- Market Size & Forecast 2019-2030, USD Million
-Oncology- Market Size & Forecast 2019-2030, USD Million
-Pain Management- Market Size & Forecast 2019-2030, USD Million
-Neurology- Market Size & Forecast 2019-2030, USD Million
-Others (Thyroid, Gynecological, etc.)- Market Size & Forecast 2019-2030, USD Million
-By End User
-Hospitals- Market Size & Forecast 2019-2030, USD Million
-Ambulatory Surgical Centers- Market Size & Forecast 2019-2030, USD Million
-Others (Specialty Clinics, Research Organizations, etc.)- Market Size & Forecast 2019-2030, USD Million
-By Region
-North America
-South America
-Europe
-The Middle East & Africa
-Asia-Pacific
Explore the Complete Analysis Report – https://www.marknteladvisors.com/research-library/radiofrequency-ablation-devices-market.html
What role do key competitors play in shaping the market, and how are they adapting to emerging trends and challenges?
Boston Scientific Corporation, Pajunk, Abbott, Medtronic, Stryker, BIOTRONIK Schweiz AG, AngioDynamics, CONMED Corporation, Lepu Medical Technology(Beijing)Co., Ltd., Arthrex, Inc., STARmed Co., Ltd., AVNS, Olympus, BVM Medical Limited (RF Medical), Johnson & Johnson Services, Inc., Others
Market research studies from MarkNtel Advisors are offered in PDF, Excel and PowerPoint formats. Within 24 hours of the payment being successfully received, the report will be sent to your email address.”
Key Questions Answered in the Research Report:
What are the industry’s overall statistics or estimates (Overview, Size- By Value, Forecast Numbers, Segmentation, Shares)?
What are the trends influencing the current scenario of the market?
What key factors would propel and impede the industry across the country?
How has the industry been evolving in terms of geography & solution adoption?
How have buying behavior, customer inclination, and expectations from product manufacturers been evolving during 2024-30?
Who are the key competitors, and what strategic partnerships or ventures are they coming up with to stay afloat during the projected time frame?
Why MarkNtel Advisors?
MarkNtel Advisors is a leading research, consulting, & data analytics firm that provides an extensive range of strategic reports on diverse industry verticals. We deliver data to a substantial & varied client base, including multinational corporations, financial institutions, governments, & individuals, among others.
Our specialization in niche industries & emerging geographies allows our clients to formulate their strategies in a much more informed way and entail parameters like Go-to-Market (GTM), product development, feasibility analysis, project scoping, market segmentation, competitive benchmarking, market sizing & forecasting, & trend analysis, among others, for 15 diverse industrial verticals.
For Media Inquiries, Please Contact:
Email: [email protected]
Sales Office: 564 Prospect St, B9, New Haven, Connecticut, USA-06511
Corporate Office: Office No.109, H-159, Sector 63, Noida, Uttar Pradesh-201301
0 notes
Text
Primary Sclerosing Cholangitis Market Size, Share and Future News by 2025-2033
The Reports and Insights, a leading market research company, has recently releases report titled “Primary Sclerosing Cholangitis Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2025-2033.” The study provides a detailed analysis of the industry, including the global Primary Sclerosing Cholangitis Market share, size, trends, and growth forecasts. The report also includes competitor and regional analysis and highlights the latest advancements in the market.
Report Highlights:
How big is the Primary Sclerosing Cholangitis Market?
The global primary sclerosing cholangitis market was valued at US$ 174.9 Million in 2024 and is expected to register a CAGR of 7.8% over the forecast period and reach US$ 370.8 Million in 2033.
What are Primary Sclerosing Cholangitis?
Primary sclerosing cholangitis (PSC) is a chronic liver condition characterized by ongoing inflammation and scarring of the bile ducts, leading to their narrowing, obstruction, and subsequent liver damage. Symptoms may include jaundice, itching, abdominal pain, and fatigue. PSC is often linked to an increased risk of liver cirrhosis and liver cancer. While the precise cause remains unclear, the disease is thought to involve autoimmune mechanisms and is frequently associated with inflammatory bowel diseases like ulcerative colitis. Treatment aims to alleviate symptoms, slow disease progression, and manage complications, with liver transplantation being a potential option for advanced stages.
Request for a sample copy with detail analysis: https://www.reportsandinsights.com/sample-request/2389
What are the growth prospects and trends in the Primary Sclerosing Cholangitis industry?
The primary sclerosing cholangitis (PSC) market growth is driven by various factors and trends. The market for primary sclerosing cholangitis (PSC) is expanding due to heightened awareness of the disease, improvements in diagnostic methods, and advancements in treatment options. Increasing recognition of PSC, particularly its links to inflammatory bowel diseases, along with the growing incidence of liver complications, is boosting demand for effective therapies. Key players in the market include pharmaceutical and biotechnology companies focusing on new drug developments and clinical trials. The market is also driven by the need for improved symptom management and potential curative approaches, such as liver transplantation. Despite challenges like high treatment costs and limited available therapies, ongoing research and innovation are contributing to the market's growth. Hence, all these factors contribute to primary sclerosing cholangitis (PSC) market growth.
What is included in market segmentation?
The report has segmented the market into the following categories:
By Type
Classic PSC
Variant PSC
PSC Associated with Autoimmune Hepatitis
PSC with Cholangiocarcinoma
By Treatment Type
Ursodeoxycholic Acid
Obeticholic Acid
Methotrexate
Corticosteroids
Others
By Route of Administration
Oral
Parental
Others
By End-User
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
North America
United States
Canada
Europe
Germany
United Kingdom
France
Italy
Spain
Russia
Poland
Benelux
Nordic
Rest of Europe
Asia Pacific
China
Japan
India
South Korea
ASEAN
Australia & New Zealand
Rest of Asia Pacific
Latin America
Brazil
Mexico
Argentina
Middle East & Africa
Saudi Arabia
South Africa
United Arab Emirates
Israel
Rest of MEA
Who are the key players operating in the industry?
The report covers the major market players including:
Acorda Therapeutics, Inc.
Gilead Sciences, Inc.
NGM Biopharmaceuticals, Inc.
Intercept Pharmaceuticals, Inc.
Falk Pharma GmbH
Allergan Plc.
Shire Plc.
Durect Corporation
Conatus Pharmaceuticals, Inc.
Sirnaomics, Inc.
Shenzhen HighTide Biopharmaceutical Ltd.
Cymabay Therapeutics
Pliant Therapeutics
Immunic AG
View Full Report: https://www.reportsandinsights.com/report/Primary Sclerosing Cholangitis-market
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
About Us:
Reports and Insights consistently mееt international benchmarks in the market research industry and maintain a kееn focus on providing only the highest quality of reports and analysis outlooks across markets, industries, domains, sectors, and verticals. We have bееn catering to varying market nееds and do not compromise on quality and research efforts in our objective to deliver only the very best to our clients globally.
Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.
Contact Us:
Reports and Insights Business Research Pvt. Ltd. 1820 Avenue M, Brooklyn, NY, 11230, United States Contact No: +1-(347)-748-1518 Email: [email protected] Website: https://www.reportsandinsights.com/ Follow us on LinkedIn: https://www.linkedin.com/company/report-and-insights/ Follow us on twitter: https://twitter.com/ReportsandInsi1
#Primary Sclerosing Cholangitis Market share#Primary Sclerosing Cholangitis Market size#Primary Sclerosing Cholangitis Market trends
0 notes
Text
According to report by IMARC Group provides the key factors driving the epidemiological trend of Cholangiocarcinoma.
0 notes
Link
0 notes
Text
Veterinary Services Strategies In The Global Market: Key Insights From The 2025 Report
The global Pancreatic And Biliary Stents Market was valued at USD 354.2 million in 2023 and is projected to reach USD 511.47 million by 2031, growing at a compound annual growth rate (CAGR) of 4.7% over the forecast period of 2024-2031. This growth is driven by the increasing prevalence of pancreatic and biliary diseases, advancements in stent technology, and the growing number of minimally invasive procedures globally.
Get Free Sample Report on Pancreatic and Biliary Stents Market
Pancreatic and biliary stents are medical devices that are used to treat various conditions of the pancreas and bile ducts, including chronic pancreatitis, bile duct obstruction, pancreatic cancer, and gallstones. These stents are inserted into the ducts to help maintain their patency, ensuring the normal flow of bile or pancreatic fluids. The increasing incidence of gastrointestinal disorders, such as pancreatitis and bile duct blockages, has significantly contributed to the demand for these devices.
Key Drivers of Market Growth
Increasing Prevalence of Pancreatic and Biliary Disorders: The global rise in pancreatic and biliary diseases, including conditions such as pancreatitis, cholangiocarcinoma (bile duct cancer), and pancreatic cancer, is one of the primary factors contributing to the growth of the pancreatic and biliary stents market. According to the World Health Organization (WHO), pancreatic cancer is one of the leading causes of cancer-related deaths worldwide. As these diseases continue to affect an increasing number of people, the demand for stents, particularly in the management of these conditions, is expected to rise significantly.
Rising Adoption of Minimally Invasive Procedures: Minimally invasive procedures, including the use of endoscopic techniques to insert pancreatic and biliary stents, are increasingly preferred due to their lower risks, shorter recovery times, and reduced discomfort for patients. The growing trend of performing complex gastrointestinal procedures with minimal incision and reduced risk of complications is driving the demand for pancreatic and biliary stents. These procedures help to address conditions such as obstructed bile ducts, improving patients' quality of life and reducing the need for traditional surgery.
Technological Advancements in Stent Designs: The development of advanced stent technologies, including drug-eluting stents (DES) and biodegradable stents, is another key factor contributing to the market's growth. Drug-eluting stents, which release medication over time to prevent stent occlusion and restenosis, are increasingly being used to improve treatment outcomes. Biodegradable stents, which dissolve naturally over time, are expected to gain popularity due to their ability to reduce the need for removal procedures. These advancements are expected to boost the effectiveness of treatments and improve patient outcomes, further driving the growth of the pancreatic and biliary stents market.
Growing Demand for Advanced Medical Treatments: As healthcare systems across the globe continue to improve, the demand for advanced medical treatments is on the rise. This includes the increased use of stents for the management of complex pancreatic and biliary conditions. Rising healthcare expenditures and the increasing availability of healthcare services in emerging economies are expected to drive the adoption of pancreatic and biliary stents in these regions, further expanding the market.
Aging Population: The aging global population is another important driver for the growth of the pancreatic and biliary stents market. Older individuals are more susceptible to pancreatic and biliary diseases due to factors such as weakened immune systems, chronic conditions, and lifestyle factors. As the population of elderly individuals continues to rise, the demand for medical devices like pancreatic and biliary stents to manage these conditions is expected to increase.
Improved Diagnosis and Awareness: As awareness of pancreatic and biliary diseases grows, more people are seeking medical attention and receiving early diagnoses. Improvements in diagnostic imaging and technologies, such as endoscopic retrograde cholangiopancreatography (ERCP), have enabled better detection of blockages, stenosis, and other conditions affecting the bile ducts and pancreas. This early detection allows for timely intervention and the increased use of stents to treat these conditions.
KEY MARKET SEGMENTATION
By Product Type
Metal Stents
Plastic Stents
By Applications
Bilio-pancreatic leakages
Pancreatic Cancer
Benign Biliary strictures
Others
By End Users
Hospitals
Ambulatory Surgical Centers
Speciality Clinics
Others
Make Enquiry about Pancreatic and Biliary Stents Market
Competitive Landscape
The pancreatic and biliary stents market is competitive, with several key players leading the industry. Prominent companies include Boston Scientific Corporation, Cook Medical, Medtronic, Abbott Laboratories, and Terumo Corporation. These companies are focused on product innovation, expanding their market presence, and forming strategic partnerships to maintain a competitive edge.
Boston Scientific Corporation: Boston Scientific offers a range of advanced pancreatic and biliary stents, including self-expanding metal stents and plastic stents, and is a leader in the market due to its continuous innovation and product development.
Cook Medical: Cook Medical is another major player in the pancreatic and biliary stents market, known for its high-quality stent offerings and its commitment to advancing minimally invasive treatments.
Medtronic: Medtronic is a leading global healthcare company that provides a wide range of stents for various applications, including pancreatic and biliary treatments. The company's strong presence in the global medical device market gives it a competitive edge.
Conclusion
The pancreatic and biliary stents market is expected to experience significant growth, driven by the increasing prevalence of pancreatic and biliary diseases, the growing demand for minimally invasive treatments, and advancements in stent technology. With a projected market value of USD 511.47 million by 2031, the market is set to benefit from innovations such as biodegradable stents, drug-eluting stents, and improvements in stent design. As the demand for advanced gastrointestinal treatments continues to rise, pancreatic and biliary stents will play a critical role in managing these complex conditions, improving patient outcomes, and contributing to the overall growth of the healthcare industry.
About US:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.
Contact Us:
Jagney Dave - Vice President of Client Engagement
Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)
#Pancreatic and Biliary Stents Market#Pancreatic and Biliary Stents Market Size#Pancreatic and Biliary Stents Market Report#Pancreatic and Biliary Stents Market Trend#Pancreatic and Biliary Stents Market Share#Pancreatic and Biliary Stents Market Growth
0 notes
Text
0 notes
Link
0 notes
Link
0 notes
Text
The Cholangiocarcinoma Market is Estimated to Witness High Growth Owing to Opportunity to Expand Treatment Options
Cholangiocarcinoma also known as bile duct cancer is a type of cancer that forms in the bile ducts. The bile ducts are thin tubes that connect the liver and gallbladder to the small intestine. They carry a fluid called bile that helps with digestion. Symptoms of cholangiocarcinoma include weight loss, abdominal pain, jaundice, and itching. Treatment options for cholangiocarcinoma include surgery, radiation therapy, chemotherapy, radiofrequency ablation and liver transplantation. The global cholangiocarcinoma market is estimated to be valued at US$ 7,275.7 Mn in 2023 and is expected to exhibit a CAGR of 7.6% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights. Market Opportunity: The opportunity to expand treatment options presents a high growth opportunity for the cholangiocarcinoma market. Currently, surgery offers the only potential cure but most patients are not eligible for surgery due to advanced stage at diagnosis. Thus, there is a need for new targeted drugs and immunotherapies to treat cholangiocarcinoma. Many novel drugs and drug combinations are being evaluated in clinical trials which have shown promising results in improving patient outcomes. The successful development of effective targeted therapies and immunotherapies will drive the market growth by providing new treatment alternatives and improving survival rates of cholangiocarcinoma patients. Porter's Analysis: Threat of new entrants: Low barriers to entry as the treatment landscape is evolving, however developing specialized products requires significant investment in R&D. Bargaining power of buyers: Buyers have moderate bargaining power as there are several treatment options available. However, demand is inelastic as the disease has no cure. Bargaining power of suppliers: Key suppliers have significant bargaining power as they provide specialized products and services required for treatment with limited substitutes. Threat of new substitutes: Threat is low as no cure currently exists and developing new treatment options requires extensive research. Competitive rivalry: High as key players compete on innovation to develop new treatment methods and devices. SWOT Analysis: Strengths: Growing awareness, research funding and clinical trials for newer treatment approaches. Established regional market leaders have significantresources for R&D. Weaknesses: Low disease awareness. Diagnosis challenges due to non-specific symptoms. High costs associated with treatment and surgery. Opportunities: Expanding patient population with aging demographics. Developing economies present untapped market potential. Personalized medicine and Combination therapy options offer growthscope. Threats: Stringent regulatory norms. Reimbursement uncertainties impact product uptake. Alternative treatment strategies like liver transplantation. Key Takeaways: The global cholangiocarcinoma market is expected to witness high growth over the forecast period of 2023 to 2030. The market size for 2024 is estimated at US$ 7,275.7 Mn registering a CAGR of 7.6% over the forecast period. Regional analysis: North America holds a dominant share due to advanced healthcare systems and patient affordability for high-cost treatments in the US. Asia Pacific continues to be the fastest growing regional market with rising disease incidence in China and Japan coupled with improving access and infrastructure. Key players: Key players operating in the cholangiocarcinoma market are Johnson & Johnson Services, Inc., Cooper Companies Inc., Lifecell Corporation (Allergan Plc), W. L. Gore & Associates, Inc., Maquet Holding B.V. & Co. KG, Becton, Dickinson and Company, Medtronic Plc, Cook Medical Inc., Baxter International Inc., and B. Braun Melsungen AG.
0 notes
Text
Bile Duct Cancer Market Is Estimated To Witness High Growth Owing To Rising Incidence of the Disease
The global Bile Duct Cancer Market is estimated to be valued at US$ 185.4 million in 2021 and is expected to exhibit a CAGR of 12.8% over the forecast period 2021-2028, as highlighted in a new report published by Coherent Market Insights.
Market Overview Bile duct cancer, also known as cholangiocarcinoma, is a rare and aggressive form of cancer that affects the bile ducts, which are tubes that carry bile from the liver to the small intestine. The market for bile duct cancer treatment is driven by the rising incidence of the disease, which is mainly attributed to factors such as increasing prevalence of risk factors like chronic liver diseases, obesity, and exposure to certain chemicals. The need for effective treatment options for bile duct cancer has led to the development of novel therapies and targeted drugs. These advancements are expected to drive market growth in the coming years.
Market Key Trends One key trend in the Bile Duct Cancer market is the increasing adoption of targeted therapies. Targeted therapies are designed to specifically attack cancer cells or block the growth of tumors by targeting specific genes or proteins. These therapies have shown promising results in clinical trials and have been proven to be more effective than traditional chemotherapy in some cases. For example, QED Therapeutics, Inc. is developing infigratinib, a targeted therapy that inhibits the FGFR gene mutations commonly found in bile duct cancer. In a phase II clinical trial, infigratinib demonstrated a 75% overall response rate in patients with FGFR2 fusion-positive advanced cholangiocarcinoma.
PEST Analysis - Political: Government policies and regulations regarding cancer research and healthcare infrastructure can impact the availability and accessibility of treatments for bile duct cancer patients. - Economic: The economic conditions of a country can affect the affordability of treatments and the willingness of patients to seek medical care. - Social: Awareness campaigns and initiatives by healthcare organizations and patient advocacy groups play a crucial role in early diagnosis and treatment of bile duct cancer. - Technological: Advancements in diagnostic techniques, such as imaging technologies and biomarker analysis, can contribute to early detection and improved treatment outcomes for bile duct cancer. Key Takeaways - The global bile duct cancer market is expected to witness high growth, exhibiting a CAGR of 12.8% over the forecast period, due to the increasing incidence of the disease and the need for effective treatment options. - Asia Pacific is expected to be the fastest-growing region in the bile duct cancer market, driven by a large patient population, improving healthcare infrastructure, and rising investments in cancer research and development. - Key players operating in the global bile duct cancer market include Incyte Corporation, Eisai Co., Ltd., QED Therapeutics, Inc., Agios Pharmaceuticals, Inc., RenovoRx, Ability Pharmaceuticals, Imbrium Therapeutics L.P., and Delcath Systems, Inc. These companies are actively involved in research and development activities and strategic collaborations to develop innovative therapies for bile duct cancer. In conclusion, the bile duct cancer market is witnessing significant growth due to the rising incidence of the disease and the development of targeted therapies. With increasing awareness, advancements in technology, and investments in cancer research, the market is expected to provide lucrative opportunities for key players in the coming years.
#Bile Duct Cancer#Bile Duct Cancer Market#Bile Duct Cancer Market Size#Bile Duct Cancer Market Share#Bile Duct Cancer Market Growth#Pharmaceutical
0 notes
Text
Primary Sclerosing Cholangitis Market Size, Share and Future News by 2025-2033
The Reports and Insights, a leading market research company, has recently releases report titled “Primary Sclerosing Cholangitis Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2025-2033.” The study provides a detailed analysis of the industry, including the global Primary Sclerosing Cholangitis Market share, size, trends, and growth forecasts. The report also includes competitor and regional analysis and highlights the latest advancements in the market.
Report Highlights:
How big is the Primary Sclerosing Cholangitis Market?
The global primary sclerosing cholangitis market was valued at US$ 174.9 Million in 2024 and is expected to register a CAGR of 7.8% over the forecast period and reach US$ 370.8 Million in 2033.
What are Primary Sclerosing Cholangitis?
Primary sclerosing cholangitis (PSC) is a chronic liver condition characterized by ongoing inflammation and scarring of the bile ducts, leading to their narrowing, obstruction, and subsequent liver damage. Symptoms may include jaundice, itching, abdominal pain, and fatigue. PSC is often linked to an increased risk of liver cirrhosis and liver cancer. While the precise cause remains unclear, the disease is thought to involve autoimmune mechanisms and is frequently associated with inflammatory bowel diseases like ulcerative colitis. Treatment aims to alleviate symptoms, slow disease progression, and manage complications, with liver transplantation being a potential option for advanced stages.
Request for a sample copy with detail analysis: https://www.reportsandinsights.com/sample-request/2389
What are the growth prospects and trends in the Primary Sclerosing Cholangitis industry?
The primary sclerosing cholangitis (PSC) market growth is driven by various factors and trends. The market for primary sclerosing cholangitis (PSC) is expanding due to heightened awareness of the disease, improvements in diagnostic methods, and advancements in treatment options. Increasing recognition of PSC, particularly its links to inflammatory bowel diseases, along with the growing incidence of liver complications, is boosting demand for effective therapies. Key players in the market include pharmaceutical and biotechnology companies focusing on new drug developments and clinical trials. The market is also driven by the need for improved symptom management and potential curative approaches, such as liver transplantation. Despite challenges like high treatment costs and limited available therapies, ongoing research and innovation are contributing to the market's growth. Hence, all these factors contribute to primary sclerosing cholangitis (PSC) market growth.
What is included in market segmentation?
The report has segmented the market into the following categories:
By Type
Classic PSC
Variant PSC
PSC Associated with Autoimmune Hepatitis
PSC with Cholangiocarcinoma
By Treatment Type
Ursodeoxycholic Acid
Obeticholic Acid
Methotrexate
Corticosteroids
Others
By Route of Administration
Oral
Parental
Others
By End-User
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
North America
United States
Canada
Europe
Germany
United Kingdom
France
Italy
Spain
Russia
Poland
Benelux
Nordic
Rest of Europe
Asia Pacific
China
Japan
India
South Korea
ASEAN
Australia & New Zealand
Rest of Asia Pacific
Latin America
Brazil
Mexico
Argentina
Middle East & Africa
Saudi Arabia
South Africa
United Arab Emirates
Israel
Rest of MEA
Who are the key players operating in the industry?
The report covers the major market players including:
Acorda Therapeutics, Inc.
Gilead Sciences, Inc.
NGM Biopharmaceuticals, Inc.
Intercept Pharmaceuticals, Inc.
Falk Pharma GmbH
Allergan Plc.
Shire Plc.
Durect Corporation
Conatus Pharmaceuticals, Inc.
Sirnaomics, Inc.
Shenzhen HighTide Biopharmaceutical Ltd.
Cymabay Therapeutics
Pliant Therapeutics
Immunic AG
View Full Report: https://www.reportsandinsights.com/report/Primary Sclerosing Cholangitis-market
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
About Us:
Reports and Insights consistently mееt international benchmarks in the market research industry and maintain a kееn focus on providing only the highest quality of reports and analysis outlooks across markets, industries, domains, sectors, and verticals. We have bееn catering to varying market nееds and do not compromise on quality and research efforts in our objective to deliver only the very best to our clients globally.
Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.
Contact Us:
Reports and Insights Business Research Pvt. Ltd. 1820 Avenue M, Brooklyn, NY, 11230, United States Contact No: +1-(347)-748-1518 Email: [email protected] Website: https://www.reportsandinsights.com/ Follow us on LinkedIn: https://www.linkedin.com/company/report-and-insights/ Follow us on twitter: https://twitter.com/ReportsandInsi1
#Primary Sclerosing Cholangitis Market share#Primary Sclerosing Cholangitis Market size#Primary Sclerosing Cholangitis Market trends
0 notes
Text
Cholangiocarcinoma Market to Exhibit Substantial Growth During the Forecast Period (2022-2032) – DelveInsight | Key Companies – AstraZeneca, Basilea, Taiho Oncology, Eisai, TransThera, Incyte, Roche
http://dlvr.it/SqQcMx
0 notes
Text
Cholangiocarcinoma Market to Exhibit Substantial Growth During the Forecast Period (2022-2032) – DelveInsight | Key Companies – AstraZeneca, Basilea, Taiho Oncology, Eisai, TransThera, Incyte, Roche
http://dlvr.it/SqQb3k
0 notes
Text
Cholangiocarcinoma Market to Exhibit Substantial Growth During the Forecast Period (2022-2032) – DelveInsight | Key Companies – AstraZeneca, Basilea, Taiho Oncology, Eisai, TransThera, Incyte, Roche
http://dlvr.it/SqQXHk
0 notes
Text
Chloangiocarcinoma (CCA) Therapeutics Market Size 2022 Growth Share, Industry Dynamics, Top Trends and Regional Analysis Forecast to 2033
The global Chloangiocarcinoma Therapeutics Market is anticipated to reach a market value of US$ 800 Million in 2023 and US$ 975.20 Million by registering a CAGR of 2% from 2023 to 2033. Inflammatory bowel disease, exposure to specific toxins, and changes in bile duct anatomy are all factors contributing to the growth of the cholangiocarcinoma therapeutics market. In the historical period from 2018 to 2022, the market for Chloangiocarcinoma therapeutics registered a CAGR of 1%.
During the forecast period 2023-2033, the Chloangiocarcinoma (CCA) Therapeutics market is expected to grow at a value of 2% CAGR, according to Future Market Insights. By the year 2033, the global market for Chloangiocarcinoma (CCA) Therapeutics is expected to rise up to a market valuation of US$ 975.20 Million. Growth of the market can be attributed to the rarity of diseases which in turn is increasing the scope for research and development of Chloangiocarcinoma (CCA) Therapeutics.
The use of precision medicine, which is a personalized approach to treatment that takes into account the patient’s genetic makeup and the specific characteristics of their cancer, is also being evaluated as a potential approach to treating CCA. In addition, researchers are also working to develop drugs that help the immune system fight cancer cells. This approach has shown promise in the treatment of other types of cancer and is being evaluated in clinical trials for CCA.
Furthermore, increasing cases of Chloangiocarcinoma in United States, China, India and Japan is creating lucrative opportunities for therapeutics of Chloangiocarcinoma. Efforts for developing innovate medication along with improved healthcare infrastructure in developed and developing regions the globe is shaping the landscape for Chloangiocarcinoma (CCA) therapeutics market.
Key Takeaways from the Market Study
The Chloangiocarcinoma (CCA) Therapeutics market is expected to grow at a value of 2% CAGR in the forecast period 2023 to 2033
By distribution channel, retail pharmacies expected to hold 40% of the market share in 2023 for Chloangiocarcinoma (CCA) Therapeutics market.
North America is expected to possess 40% market share for cholangiocarcinoma therapeutics market in 2023.
Asia Pacific is expected to hold 35% market share for Chloangiocarcinoma (CCA) therapeutics market in 2023.
“Increasing research and development activities for innovating medications and therapies for treating Chloangiocarcinoma (CCA) Therapeutics market.” states an FMI analyst
Competitive Landscape
Key players in the Chloangiocarcinoma therapeutics market are AstraZeneca, Decalth Systems, Basilea Pharmaceutica, Taiho Oncology, Eisai Pharmaceuticals, TransThera Sciences, Incyte Corporation, Roche, Agios Pharmaceuticals and Servier Pharmaceuticals
AstraZeneca, a key player in the Chloangiocarcinoma (CCA) therapeutics market is focusing on undertaking extensive research and development for innovating medications to reduce the intensity of the pain caused by the ailment.
Taiho Oncology, another key player in the Chloangiocarcinoma (CCA) therapeutics market is planning to integrate technology to maximize the benefit of immunotherapy.
For More Information: https://www.futuremarketinsights.com/reports/chloangiocarcinoma-therapeutics-market
More Valuable Insights
Future Market Insights, in its new offering, presents an unbiased analysis of the global Chloangiocarcinoma (CCA) therapeutics market, presenting historical analysis from 2018 to 2022 and forecast statistics for the period of 2023 to 2033.
The study reveals essential insights on the basis of treatment type (Chemotherapy, Targeted Therapy, Immunotherapy), distribution channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), regions (North America, Latin America, Europe, East Asia, South Asia, Oceania and Middle East & Africa).
Key Segments Profiled in the Chloangiocarcinoma (CCA) Therapeutics Survey
Treatment Type:
Chemotherapy
Gemcitabine
Cisplatin
Oxaliplatin
Capecitabine
5 fluorouracil (5-FU)
Targeted Therapy
Pemigatinib
Infigratinib (Phase 3)
Ivosidenib (Phase 3)
Immunotherapy
Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
0 notes